Eicosatetraynoic acid

Eicosatetraynoic acid dose-dependently reduces MDA production in cultured human umbilical vein endothelial cells co-incubated with low-density lipoprotein^[1].
Eicosatetraynoic acid (40 μM; 4-72 h) reversibly inhibits DNA synthesis and blocks the proliferation of PC3, U937 and A172 cells without inducing significant cytotoxicity^[2].
Eicosatetraynoic acid (40 μM; 3-7 d) induces partial monocyte-like differentiation in U937 cells, and induces partial glial-like differentiation in A172 cells after 72 h of incubation; in addition, the differentiation of U937 cells progresses gradually over 5 to 7 days^[2].
Incubation with eicosatetraynoic acid (40 μM; 72 h) for 72 h induces cell type-specific ultrastructural changes, including severe oxidative stress-related mitochondrial damage in PC3 cells, milder damage in A172 cells, and immature monocyte morphology in U937 cells^[2].
Eicosatetraynoic acid (40 μM) rapidly regulates multiple signal transduction pathways in PC3 and U937 cells, including increasing membrane fluidity and intracellular Ca²⁺ levels, inhibiting O₂ uptake, reversibly blocking DNA synthesis, downregulating c-myc, inhibiting eicosanoid synthesis, and altering the localization of protein kinase C^[2].
Eicosatetraynoic acid non-selectively inhibits 12-lipoxygenase (ID₅₀ = 4 μM) and fatty acid cyclooxygenase (ID₅₀ = 8 μM) in washed human platelets^[3].
Eicosatetraynoic acid (79-316 μM) specifically and effectively blocks the replication of orthopoxviruses (vaccinia, vaccinia vaccine, and ectromelia viruses)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.